|1.||Furukawa, Koichi: 21 articles (04/2015 - 03/2003)|
|2.||Furukawa, Keiko: 16 articles (04/2015 - 06/2003)|
|3.||Ladisch, Stephan: 16 articles (10/2014 - 03/2002)|
|4.||Pérez, Rolando: 11 articles (01/2012 - 03/2002)|
|5.||Ravindranath, Mepur H: 11 articles (02/2008 - 01/2002)|
|6.||Rayman, Patricia: 10 articles (01/2015 - 04/2003)|
|7.||Liu, Yihui: 10 articles (10/2014 - 03/2002)|
|8.||Morton, Donald L: 10 articles (06/2014 - 01/2002)|
|9.||Biswas, Kaushik: 9 articles (01/2015 - 09/2004)|
|10.||Finke, James H: 9 articles (01/2015 - 04/2003)|
02/15/2001 - "Predominance of b pathway tumor gangliosides correlated with improved outcome. "
01/01/2008 - "The results of this study indicate that comparative quantitative and compositional analysis of both preoperative and postoperative serum gangliosides may provide useful information concerning tumor progression, surgical success and prognosis."
05/15/2007 - "Previous studies from our laboratory demonstrated the role of tumor-derived gangliosides as important mediators of T cell apoptosis, and hence, as one mechanism by which tumors evade immune destruction. "
07/01/2006 - "Although gangliosides have long been known to suppress T-cell immunity, few studies have examined the effect of human tumor-derived gangliosides on immune responses. "
04/01/2003 - "Most tumor cells synthesize and shed large amounts of gangliosides into their microenvironment, and many studies have unraveled their immunosuppressive properties. "
|2.||Diabetic Neuropathies (Diabetic Neuropathy)
04/01/1984 - "[Attempts at cure with high doses of gangliosides in diabetic autonomic neuropathy]."
07/01/1986 - "Further studies employing greater numbers of patients and higher doses are required to confirm the efficacy of gangliosides in diabetic neuropathy."
08/01/1989 - "The efficacy of gangliosides in enhancing axonal regeneration and maturation in the early stages of diabetic neuropathy was assessed by quantitative analysis of immunostained serial sections of the sciatic nerve. "
01/01/1993 - "Diabetic neuropathy and the pharmacology of gangliosides."
01/01/1993 - "Clinical uses of gangliosides in diabetic neuropathy."
01/01/2001 - "There is not enough evidence to conclude that gangliosides are beneficial in acute stroke. "
01/01/2000 - "There is not enough evidence to conclude that gangliosides are beneficial in acute stroke. "
01/01/2001 - "Randomised trials of gangliosides compared with placebo or standard treatment in people with definite or presumed ischaemic stroke. "
01/01/2000 - "Randomised trials of gangliosides compared with placebo or standard treatment in people with definite or presumed ischaemic stroke. "
09/01/2002 - "Gangliosides for acute ischemic stroke."
|4.||Melanoma (Melanoma, Malignant)
01/01/2011 - "Augmented total gangliosides serum levels after melanoma adjuvant treatment were predictive for decreased overall survival, whereas decreased total gangliosides serum levels were predictable for improved overall survival. "
12/02/1991 - "Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. "
12/01/2007 - "Randomized trials using allogeneic melanoma cells/lysates or gangliosides have not demonstrated a clinical benefit, although in some trials, clinical benefit was seen in large subsets. "
06/01/2006 - "In the present study, we analysed the effect of GM3 and GD3 gangliosides purified from human melanoma tumours on the phenotypic and functional maturation of human epidermal Langerhans cells (LCs), the first immune barrier against the tumour cells. "
03/15/1988 - "These results appear to have implications for the use of MAbs against gangliosides in therapy of melanoma and in the study of melanocytic differentiation."
03/01/2014 - "Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission."
03/01/1985 - "Studies on the turnover and subcellular localization of membrane gangliosides in cultured neuroblastoma cells."
03/01/1984 - "Our previous studies have demonstrated that a mixture of bovine brain gangliosides ( BBG ) applied to Neuro-2a neuroblastoma cells markedly increased the degree and rate of neurite formation. "
02/01/2014 - "Using Neuro-2a cells, a mouse neuroblastoma cell line, TeNT HCR (HCR/T) and TeNT(RY) were found to bind gangliosides with similar affinities and specificities, consistent with the HCR domain containing receptor binding function. "
02/01/2013 - "The sensitivity of human neuroblastoma cell lines to HVJ-E correlated with the expression level of gangliosides, Sialylparagloboside (SPG) and GD1a, receptors for HVJ. "
|2.||Immunoglobulin M (IgM)
|4.||Immunoglobulin G (IgG)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Transplantation (Transplant Recipients)